Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1994;72(5):761–770.

Sex-specific differences in mortality after high-titre measles immunization in rural Senegal.

P Aaby 1, B Samb 1, F Simondon 1, K Knudsen 1, A M Seck 1, J Bennett 1, L Markowitz 1, P Rhodes 1, H Whittle 1
PMCID: PMC2486568  PMID: 7955026

Abstract

Administration of high-titre measles vaccine (Edmonston-Zagreb (EZ) at > 10(5) plaque-forming units (PFU) per dose) before the age of 9 months has been recommended in areas with high measles mortality before the routine age of immunization after 9 months. The study compares the long-term survival after high-titre measles immunization at 5 months of age with that following routine immunization with standard-titre vaccine at 10 months of age. At 5 months of age the high-titre group received Edmonston-Zagreb (EZ-HT, 5 months) or Schwarz (SW-HT, 5 months) at titres > 10(5) PFU per dose, while the standard-titre group received placebo at 5 months of age and < 10(4) PFU per dose of Schwarz vaccine at 10 months (SW-std, 10 months). All the children were followed up to at least 36 months of age. The mortality ratio (MR) for infants in the EZ-HT, 5 months and SW-HT, 5 months groups was 1.32 (P = 0.089) and 1.45 (P = 0.092), respectively, which did not differ significantly from that of recipients of the SW-std, 10 months. The higher MR among recipients of the high-titre vaccines was due to the significantly lower survival among females compared with the females who received SW-std vaccine (EZ-HT, 5 months MR = 1.76, P = 0.013; SW-HT, 5 months MR = 2.14, P = 0.017). For children aged 5-10 months the high-titre measles vaccine did not increase mortality relative to unvaccinated children who had received placebo.

Full text

PDF
761

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaby P., Bukh J., Hoff G., Leerhøy J., Lisse I. M., Mordhorst C. H., Pedersen I. R. High measles mortality in infancy related to intensity of exposure. J Pediatr. 1986 Jul;109(1):40–44. doi: 10.1016/s0022-3476(86)80569-8. [DOI] [PubMed] [Google Scholar]
  2. Aaby P., Bukh J., Kronborg D., Lisse I. M., da Silva M. C. Delayed excess mortality after exposure to measles during the first six months of life. Am J Epidemiol. 1990 Aug;132(2):211–219. doi: 10.1093/oxfordjournals.aje.a115650. [DOI] [PubMed] [Google Scholar]
  3. Aaby P., Clements C. J. Measles immunization research: a review. Bull World Health Organ. 1989;67(4):443–448. [PMC free article] [PubMed] [Google Scholar]
  4. Aaby P., Knudsen K., Jensen T. G., Thårup J., Poulsen A., Sodemann M., da Silva M. C., Whittle H. Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage. J Infect Dis. 1990 Nov;162(5):1043–1048. doi: 10.1093/infdis/162.5.1043. [DOI] [PubMed] [Google Scholar]
  5. Aaby P., Knudsen K., Whittle H., Lisse I. M., Thaarup J., Poulsen A., Sodemann M., Jakobsen M., Brink L., Gansted U. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. J Pediatr. 1993 Jun;122(6):904–908. doi: 10.1016/s0022-3476(09)90015-4. [DOI] [PubMed] [Google Scholar]
  6. Aaby P., Samb B., Simondon F., Knudsen K., Seck A. M., Bennett J., Whittle H. Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal. Am J Epidemiol. 1993 Nov 1;138(9):746–755. doi: 10.1093/oxfordjournals.aje.a116912. [DOI] [PubMed] [Google Scholar]
  7. Aaby P., Samb B., Simondon F., Whittle H., Seck A. M., Knudsen K., Bennett J., Markowitz L., Rhodes P. Child mortality after high-titre measles vaccines in Senegal: the complete data set. Lancet. 1991 Dec 14;338(8781):1518–1519. doi: 10.1016/0140-6736(91)92330-5. [DOI] [PubMed] [Google Scholar]
  8. Dabis F., Sow A., Waldman R. J., Bikakouri P., Senga J., Madzou G., Jones T. S. The epidemiology of measles in a partially vaccinated population in an African city: implications for immunization programs. Am J Epidemiol. 1988 Jan;127(1):171–178. doi: 10.1093/oxfordjournals.aje.a114778. [DOI] [PubMed] [Google Scholar]
  9. Diaz-Ortega J. L., Luna-Abascal M., Valdespino J. L., Sepulveda J., Markowitz L. E., Zell E. R. Mortality and morbidity after high titre measles vaccine in Mexico. Lancet. 1992 Oct 10;340(8824):924–924. doi: 10.1016/0140-6736(92)93345-n. [DOI] [PubMed] [Google Scholar]
  10. Garenne M., Aaby P. Pattern of exposure and measles mortality in Senegal. J Infect Dis. 1990 Jun;161(6):1088–1094. doi: 10.1093/infdis/161.6.1088. [DOI] [PubMed] [Google Scholar]
  11. Loening W. E., Coovadia H. M. Age-specific occurrence rates of measles in urban, peri-urban, and rural environments: implications for time of vaccination. Lancet. 1983 Aug 6;2(8345):324–326. doi: 10.1016/s0140-6736(83)90299-4. [DOI] [PubMed] [Google Scholar]
  12. Markowitz L. E., Sepulveda J., Diaz-Ortega J. L., Valdespino J. L., Albrecht P., Zell E. R., Stewart J., Zarate M. L., Bernier R. H. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med. 1990 Mar 1;322(9):580–587. doi: 10.1056/NEJM199003013220903. [DOI] [PubMed] [Google Scholar]
  13. Samb B., Aaby P., Whittle H., Seck A. M., Simondon F. Protective efficacy of high-titre measles vaccines administered from the age of five months: a community study in rural Senegal. Trans R Soc Trop Med Hyg. 1993 Nov-Dec;87(6):697–701. doi: 10.1016/0035-9203(93)90301-6. [DOI] [PubMed] [Google Scholar]
  14. Taylor W. R., Mambu R. K., ma-Disu M., Weinman J. M. Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life. Am J Epidemiol. 1988 Apr;127(4):788–794. doi: 10.1093/oxfordjournals.aje.a114860. [DOI] [PubMed] [Google Scholar]
  15. Tidjani O., Grunitsky B., Guérin N., Lévy-Bruhl D., Lecam N., Xuereff C., Tatagan K. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months. Lancet. 1989 Dec 9;2(8676):1357–1360. doi: 10.1016/s0140-6736(89)91967-3. [DOI] [PubMed] [Google Scholar]
  16. Whittle H. C., Campbell H., Rahman S., Armstrong J. R. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet. 1990 Oct 27;336(8722):1046–1048. doi: 10.1016/0140-6736(90)92501-8. [DOI] [PubMed] [Google Scholar]
  17. Whittle H., Hanlon P., O'Neill K., Hanlon L., Marsh V., Jupp E., Aaby P. Trial of high-dose Edmonston-Zagreb measles vaccine in the Gambia: antibody response and side-effects. Lancet. 1988 Oct 8;2(8615):811–814. doi: 10.1016/s0140-6736(88)92781-x. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES